The Alarming Rise of Synthetic Opioids: What Healthcare Professionals Should Know
Omid Mehrpour
Post on 31 May 2024 . Read 4 min read
Omid Mehrpour
Post on 31 May 2024 . Read 4 min read
Synthetic opioids like fentanyl, methadone, and buprenorphine have become both a medical breakthrough and a public health challenge. Despite their approved medical uses, the increasing number of synthetic opioid overdoses, which resulted in over 80,000 deaths in 2021 alone, highlights a critical issue that healthcare professionals must urgently address. The misuse of powerful substances like fentanyl, carfentanil, and new variants like xylazine and protonitazene drives this crisis. With over one million drug overdose deaths since 1999, the CDC is actively working to combat this epidemic through surveillance and resource distribution.
In this blog, we will explore the types of novel synthetic opioids entering the market, the health risks they pose, the challenges in detecting them, and contemporary treatment approaches. This comprehensive guide aims to equip healthcare professionals with the knowledge to tackle this dire crisis.
N-desethyl isotonitazene has recently entered the U.S. recreational drug market, raising concerns due to its potency and increasing prevalence.
Isotonitazene (ISO) and its variants are structurally similar to fentanyl but have chemical differences that make them even more dangerous. Sourced primarily from China, these substances are often mixed with heroin or fentanyl, significantly increasing their risk of overdose.
Butonitazene, another nitazene synthetic opioid, was critically reviewed by the WHO in July 2023 due to its rising prominence and associated health risks.
Synthetic opioids are often sold under various street names like U-47700, Pinky, and OxyCodone, making it difficult for authorities to identify and control their distribution accurately. This complicates efforts to monitor and regulate these dangerous substances.
With the evolving landscape of synthetic drug abuse, detecting novel synthetic opioids requires enhanced toxicology testing methods. Recent advancements like Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) have proven effective in identifying substances like Para-fluorobutyrylfentanyl (FIBF), furanylfentanyl, and U-47700. These methods help law enforcement and healthcare professionals keep up with the dynamic nature of synthetic opioid markets.
Novel Synthetic Opioids (NSOs), especially fentanyl analogs, have emerged as a significant public health threat, comparable to traditional illicit drugs. Law enforcement agencies have reported an increase in the seizure of substances like acetyl fentanyl and butyryl fentanyl, alongside non-fentanyl compounds such as U-47700. The increase in these seizures highlights the ongoing challenges in drug enforcement and public safety.
Synthetic opioids primarily target the mu-opioid receptor (MOR) in the central nervous system, leading to analgesia, euphoria, and respiratory depression. These opioids often have a higher binding affinity for MOR than traditional opioids like morphine, making them significantly more potent and dangerous. The pharmacokinetics of these drugs, including their absorption, distribution, metabolism, and excretion (ADME), play a crucial role in their effects and risks.
Different populations, including adolescents, pregnant women, and individuals with co-occurring mental health disorders, face unique risks from synthetic opioids. Understanding how these substances affect specific groups is vital for developing targeted prevention and treatment strategies.
The immediate health risks of synthetic opioids include respiratory depression, overdose, and neurological effects. Long-term consequences include the potential for viral infections, opioid use disorder (OUD), and dependency. Addressing these health risks requires a multi-faceted approach from healthcare professionals.
Due to the potency of novel synthetic opioids, standard doses of naloxone may be insufficient. It is recommended to start with a 2 mg dose of naloxone to counteract the effects effectively. Public education on the availability and use of naloxone is also crucial in reducing opioid-related deaths.
The FDA has approved three main medications for treating opioid use disorder: methadone, buprenorphine, and naltrexone. These medications play a critical role in recovery by either suppressing withdrawal symptoms or blocking the euphoric effects of opioids. Naloxone remains a life-saving medication for emergency overdose situations.
Improving opioid prescribing practices, providing support and crisis helplines, and offering education and training for healthcare professionals are essential strategies for preventing opioid misuse and supporting recovery efforts.
Good Samaritan Laws protect individuals who administer naloxone during an overdose emergency from legal liabilities. Public education campaigns and community-based programs are vital in increasing awareness about the dangers of synthetic opioids and the availability of life-saving treatments.
The synthetic opioid crisis requires a comprehensive and multi-faceted approach that includes enhanced detection methods, public education, access to naloxone, and support for vulnerable populations. By equipping healthcare professionals with the necessary knowledge and tools, we can reduce the devastating impact of synthetic opioids on our communities.
Related blog: Ketamine vs. Esketamine: Are These Mind-Altering Medications Safe for Treating Depression?
© All copyright of this material is absolute to Medical toxicology
Dr. Omid Mehrpour is a distinguished medical toxicologist known for his extensive clinical and research expertise. He focuses on understanding and treating toxic exposures. Renowned for his ability to diagnose and manage poisoning cases, Dr. Mehrpour has authored numerous impactful publications and is dedicated to educating future medical toxicologists. His innovative approach and commitment to patient care make him a leading figure in medical toxicology.
[1] - https://www.talktofrank.com/drug/synthetic-opioids
[2] - https://www.dea.gov/sites/default/files/2020-06/Synthetic%20Opioids-2020.pdf
[3] - https://www.dea.gov/factsheets/synthetic-opioids
[4] - https://www.cdc.gov/opioids/data/index.html
[5] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531094/
[6] - https://www.cdc.gov/opioids/data/analysis-resources.html
[7] - https://www.cbo.gov/system/files/2022-09/58221-opioid-crisis.pdf
[8] - https://www.drugsandalcohol.ie/38001/
[9] - https://www.dea.gov/stories/2022/2022-06/2022-06-01/new-dangerous-synthetic-opioid-dc-emerging-tri-state-area
[10] - https://www.unodc.org/LSS/Announcement/Details/5e522b74-ceb3-455d-95f9-8fb49e01ecf5
[11] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573780/
[12] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352208/
[13] - https://journals.lww.com/journaladdictionmedicine/fulltext/2017/08000/misuse_of_novel_synthetic_opioids__a_deadly_new.5.aspx
[14] - https://www.dhs.gov/science-and-technology/news/2024/02/01/feature-article-knowledge-power-fight-against-synthetic-opioids
[15] - https://www.who.int/news-room/fact-sheets/detail/opioid-overdose
[16] - https://www.cdc.gov/opioids/basics/epidemic.html
[17] - https://www.cdc.gov/opioids/basics/fentanyl.html
[18] - https://www.ncbi.nlm.nih.gov/books/NBK470415/
[19] - https://www.emcdda.europa.eu/publications/european-drug-report/2023/new-psychoactive-substances_en
[20] - https://www.nature.com/articles/s41598-020-68348-w
[21] - https://www.samhsa.gov/find-help/national-helpline
[22] - https://www.psychiatry.org/patients-families/opioid-use-disorder
[23] - https://msdh.ms.gov/page/44,0,382.html
[24] - https://www.hhs.gov/surgeongeneral/reports-and-publications/addiction-and-substance-misuse/advisory-on-naloxone/index.html
[25] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286889/